| DC8182 |
Bempedoic Acid(ETC-1002;ESP-55016)
Featured
|
ETC-1002(ESP-55016) is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule; activator of hepatic AMP-activated protein kinase (AMPK); also has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM). |
|
| DC8118 |
GKT137831(Setanaxib)
Featured
|
GKT137831 is a novel and specific dual Nox1/Nox4 inhibitor with Ki of 140±40 nM and 110±30 nM; a potent inhibitor of fibrosis and hepatocyte apoptosis. |
|
| DC10003 |
PF-06291874（glucagon receptor antagonists-4）
Featured
|
glucagon receptor antagonists-4 is a highly potent glucagon receptor antagonist. |
|
| DC9299 |
GRA Ex-25
Featured
|
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. |
|
| DC9712 |
Iinerixibat |
GSK2330672 is a highly potent, nonabsorbable ASBT(apical sodium-dependent bile acid transporter) inhibitor (hASBT IC50=42 ± 3 nM) . |
|
| DCAPI1506 |
Mitiglinide Calcium |
Inhibitor of ATP-sensitive K+ channel activity in MIN 6 cells. Has also been shown to bind sulfonylurea receptors as well. |
|
| DCAPI1573 |
Ipragliflozin (ASP1941)
Featured
|
Ipragliflozin (ASP1941) is a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects |
|
| DC11190 |
JTT-551 |
JTT-551 (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR. |
|
| DC11191 |
JTT-551 sodium |
JTT-551 sodium (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR. |
|
| DC10278 |
LGD-6972
Featured
|
LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research. |
|
| DC1105 |
Linagliptin (BI-1356)
Featured
|
Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. |
|
| DC10765 |
LX-2761 |
LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control. |
|
| DC7921 |
Sotagliflozin (LX-4211)
Featured
|
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents. |
|
| DC11681 |
LY2922470 |
LY2922470 (LY-2922470) is a potent, selective, orally available GPR40 agonist with EC50 of 7 nM. |
|
| DC8041 |
MK-0941
Featured
|
MK-0941 is a novel Glucokinase activator (GKA) |
|
| DC7585 |
Omarigliptin
Featured
|
MK-3102 (MSD) is a novel DPP-4 Inhibitor, which improves glycaemic control with low risk of symptomatic hypoglycaemia. |
|
| DC5034 |
MK8245
Featured
|
MK-8245 is an liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy. |
|
| DC12020 |
MK-8722
Featured
|
MK-8722 is a systemic, Direct Pan-Activator of AMP-Activated Protein Kinase. |
|
| DC12255 |
MLN-4760
Featured
|
MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM). |
|
| DC4136 |
NPS-2143 HCL |
NPS 2143 hydrochloride is a selective CaSR (Ca2+-sensing receptor) inhibitor and antagonist, shown to block increases in cytoplasmic Ca2+ concentrations elicited by human Ca2+ receptors expressed in HEK293 cells with an IC50 of 43 nM. NPS 2143 hydrochlori |
|
| DC7214 |
NPS-2143(SB 262470A ) |
NPS-2143(SB 262470A ) is a selective potent calcium ion-sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroid hormone secretion, respectively. |
|
| DC10807 |
O304
Featured
|
O304 is a novel AMPK activator. |
|
| DC6401 |
Odanacatib (MK 0822)
Featured
|
Odanacatib (MK 0822) is a potent, selective, and neutral inhibitor of human and rabbit cathepsin K with IC50 of 0.2 nM and 1 nM , respectively. |
|
| DC7109 |
Otenabant (CP-945598 free base)
Featured
|
Otenabant (CP945598) is a recently discovered selective, high affinity, competitive CB1 receptor antagonist with Ki of 0.7 nM. |
|
| DC7227 |
PF-04620110
Featured
|
PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM. |
|
| DC3108 |
PF-04971729 (Ertugliflozin)
Featured
|
PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus. |
|
| DC10050 |
PF05175157
Featured
|
PF-05175157 is a potent and selective inhibitor of both acetyl-CoA carboxylase isoform ACC1 located primarily in liver and adipose tissue and isoform ACC2 dominant in skeletal and heart muscle, with IC50 values of 27 nM and 33 nM, respectively. |
|
| DC11466 |
PF-06409577
Featured
|
PF-06409577 is a potent and selective allosteric activator of AMPK α1β1γ1 isoform with an EC50 of 7 nM. |
|
| DC9454 |
Ro 28-1675 |
Ro 28-1675 (Ro 0281675) is a potent allosteric GK activator with a SC1.5 value of 0.24± 0.0019 uM. |
|
| DC9084 |
Rosiglitazone base |
Rosiglitazone(BRL-49653) is a high-affinity selective agonist of the peroxisome proliferator-activated receptor-γ(PPARγ). |
|
